Impact of Obstructive Sleep Apnea on Diabetic Retinopathy Progression and Systemic Complications.

ABSTRACT

PURPOSE: Evaluate the risk of diabetic retinopathy progression and systemic vascular events, including death, in patients with non-proliferative diabetic retinopathy (NPDR) with obstructive sleep apnea (OSA). DESIGN: Retrospective cohort study. METHODS: Electronic chart query using TriNetX (Cambridge, MA, USA), an electronic health records network comprising data from over 124 million patients. Patients with NPDR with and without OSA were identified. Patients were excluded if they had history of proliferative disease (PDR), diabetic macular edema (DME), or prior ocular intervention (intravitreal injection, laser, or pars plana vitrectomy). Propensity score matching was performed to control for baseline demographics and comorbidities. Rate of progressing to vision threatening complications (VTCs), need for ocular intervention, and systemic events was measured at 1, 3, and 5 years. RESULTS: 11,931 patients in each group were analyzed after propensity score matching. There was elevated risk of PDR in the OSA cohort at 1 (RR 1.34, P<0.001), 3 (RR 1.31, P<0.001), and 5 years (RR 1.28, P<0.001). There was elevated risk of DME in the OSA group at all time points 1 (RR 1.31, P<0.001), 3 (RR 1.19, P<0.001), and 5 years (RR 1.18, P<0.001). With respect to ocular interventions, there was an increased risk of intravitreal injection in OSA patients at 1 (RR 1.59, P<0.001), 3 (RR 1.58, P<0.001), and 5 years (RR 1.54, P<0.001), and similar trends were noted with laser photocoagulation, but not vitrectomy. Regarding systemic events, NPDR patients with OSA had a greater risk of stroke (1 year RR 1.80, P<0.001; 3 year RR 1.56, P<0.001; 5 year RR 1.49, P<0.001), myocardial infarction (1 year RR 1.51, P<0.001; 3 year RR 1.46, P<0.001; 5 year RR 1.43, P<0.001), and death (1 year RR 1.31, P<0.001; 3 year RR 1.19, P<0.001; 5 year RR 1.15, P<0.001). CONCLUSIONS: There is an increased rate of DR progression to VTCs, need for ocular intervention, and systemic complications, including death, for patients with OSA. We emphasize the need for improved screening measures of patients with NPDR and potential OSA.